Uppsala University, Department of Public Health/Geriatrics, Rudbeck Laboratory, Uppsala, Sweden.
Neurosci Lett. 2010 Jan 22;469(2):265-7. doi: 10.1016/j.neulet.2009.12.011. Epub 2009 Dec 23.
Recently, the P86L alteration in CALHM1 (calcium homeostasis modulator-1) was reported to be associated with Alzheimer's disease (AD). Moreover, the risk allele increased amyloid-beta (A beta) levels in conditioned media from cultured cells. Therefore, we hypothesized that CALHM1 P86L may modulate A beta or tau levels in cerebrospinal fluid (CSF). Nearly 200 individuals with AD or other cognitive disorders were included for CSF analysis and CALHM1 genotyping. No significant differences in CSF levels of A beta 42, tau or phospho-tau were found across the various CALHM1 genotypes. In conclusion, we found no evidence that CALHM1 P86L is associated with altered CSF levels of the investigated AD biomarkers.
最近，CALHM1（钙稳态调节剂-1）中的 P86L 改变与阿尔茨海默病（AD）有关。此外，风险等位基因增加了培养细胞条件培养基中的淀粉样蛋白-β（Aβ）水平。因此，我们假设 CALHM1 P86L 可能调节脑脊液（CSF）中的 Aβ或 tau 水平。将近 200 名患有 AD 或其他认知障碍的个体被纳入 CSF 分析和 CALHM1 基因分型。在不同的 CALHM1 基因型中，Aβ42、tau 或磷酸化 tau 的 CSF 水平没有显著差异。总之，我们没有发现证据表明 CALHM1 P86L 与所研究的 AD 生物标志物的 CSF 水平改变有关。
